Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Share-based Compensation came in at $40.0 million in Q2 2026, up 5.26% YoY from $38.0 million in Q2 2025, and down 6.98% on a QoQ basis from $43.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Share-based Compensation data on file, last reported at $40.0 million in Q2 2026.
- Quarterly Share-based Compensation rose 5.26% year-over-year to $40.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $168.0 million (up 24.44% YoY) and the FY2025 annual result came in at $157.0 million, up 27.64% from the prior year.
- Share-based Compensation fell to $40.0 million in Q2 2026, from $43.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $51.0 million in Q4 2025 to a low of $24.0 million in Q1 2022.
- A 5-year average of $33.8 million and a median of $33.0 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation slipped 23.08% — and 2025, when it jumped 50.0%.
- Tracing TEVA's Share-based Compensation over 5 years: stood at $36.0 million in 2022, then decreased by 22.22% to $28.0 million in 2023, then rose by 21.43% to $34.0 million in 2024, then jumped by 50.0% to $51.0 million in 2025, then fell by 21.57% to $40.0 million in 2026.
- The last three Share-based Compensation figures came in at $40.0 million (Q2 2026), $43.0 million (Q1 2026), and $51.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 31.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.00 Mn |
| Jun 30, 2026 | 40.00 Mn |
| Mar 31, 2026 | 43.00 Mn |
| Mar 31, 2026 | 43.00 Mn |
| Dec 31, 2025 | 51.00 Mn |
| Dec 31, 2025 | 51.00 Mn |
| Sep 30, 2025 | 34.00 Mn |
| Sep 30, 2025 | 34.00 Mn |
| Jun 30, 2025 | 38.00 Mn |
| Jun 30, 2025 | 38.00 Mn |
| Mar 31, 2025 | 34.00 Mn |
| Mar 31, 2025 | 34.00 Mn |
| Dec 31, 2024 | 34.00 Mn |
| Dec 31, 2024 | 34.00 Mn |
| Sep 30, 2024 | 29.00 Mn |
| Sep 30, 2024 | 29.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Mar 31, 2024 | 28.00 Mn |
| Mar 31, 2024 | 28.00 Mn |